

Opportunity Title: FDA Bioanalytical Research Fellowship

Opportunity Reference Code: FDA-CDER-2023-1339

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CDER-2023-1339

How to Apply *Connect with ORISE...on the GO!* Download the new ORISE GO mobile app in the [Apple App Store](#) or [Google Play Store](#) to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A complete application consists of:

- An application
- Transcripts – [Click here for detailed information about acceptable transcripts](#)
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.CDER@oraui.org. Please include the reference code for this opportunity in your email.

Application Deadline 12/29/2023 3:00:00 PM Eastern Time Zone

Description *Applications will be reviewed on a rolling-basis.

CDER Office/Lab and Location: A research opportunity is available in the Office of Clinical Pharmacology (OCP), Division of Applied Regulatory Science (DARS), Food and Drug Administration (FDA) located in Silver Spring, Maryland. This is a collaborative research project in the Center for Drug Evaluation and Research (CDER). CDER performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the FDA, CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. This research covers more than just medicines.

Research Project: The project will play a key role in advancing the regulatory research within DARS by contributing to developing and validating bioanalytical assays to support in-vitro, preclinical and clinical studies. This project will support the clinical studies of opioids to investigate the effect of psychotropic drugs on opioid-induced respiratory depression, eventually informing the labeling text on the concurrent use of opioids and psychotropic drugs. The aim is to understand why certain drugs elicit toxicity in humans that were undetected in animal studies.

Under the guidance of a mentor, the participant will learn how to develop assays to quantify the drug and/or its metabolite levels in blood (plasma or serum), validate robust bioanalytical assays for quantifying small and large drug molecules and biomarkers, and learn about automating sample preparation in a bioanalytical lab for higher throughput of preclinical and clinical pharmacokinetic samples.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between



ORISE GO

The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!

Visit ORISE GO 

GET IT ON
 Google Play

Download on the
 App Store

Opportunity Title: FDA Bioanalytical Research Fellowship

Opportunity Reference Code: FDA-CDER-2023-1339

DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA Ethics Requirements

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see [FDA Ethics for Nonemployee Scientists](#).

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications The qualified candidate should have received or be currently pursuing a master's or doctoral degree in one of the relevant fields. Degree must have been received within the past five years. Prior working experience with analytical instruments HPLC, LC-MS/MS is an advantage.

Eligibility Requirements

- **Degree:** Master's Degree or Doctoral Degree received within the last 60 months or anticipated to be received by 12/29/2023 12:00:00 AM.
- **Discipline(s):**
 - **Chemistry and Materials Sciences** ([12](#))
 - **Life Health and Medical Sciences** ([7](#))

Opportunity Title: FDA Bioanalytical Research Fellowship

Opportunity Reference Code: FDA-CDER-2023-1339

Affirmation I have lived in the United States for at least 36 out of the past 60 months.
(36 months do not have to be consecutive.)

I have read the FDA Ethics Requirements.